What were Indoco Remedies Ltd's latest quarterly results?
Indoco Remedies Ltd's latest quarterly results (Mar 2026) show
- PAT Growth YoY: +41.5%
- Revenue Growth YoY: +22.1%
- Operating Margin: 10.0%
Indoco Remedies Ltd: Stock Analysis & Fundamentals
Updated this weekIndoco Remedies Ltd (Pharma - Formulators) — fundamental analysis, earnings data, and key metrics. ROE: -9.4%. This stock is not currently in the Nifty 500 momentum outperformers list.
Indoco Remedies Ltd Key Facts
Key Numbers
Current Price
₹237
Dividend Yield
0.08%
Market Cap
2.2K Cr
Valuation
N/AOther Top Pharma - Formulators Stocks Beating Nifty 500
Frequently Asked Questions: Indoco Remedies Ltd
Based on publicly available financial data. This is educational research, not investment advice.
What is Indoco Remedies Ltd's price-to-book ratio?
Indoco Remedies Ltd's price-to-book ratio is 2.3x.
- Price-to-Book (P/B): 2.3x
- Book Value per Share: ₹102
- Current Price: ₹237
Is Indoco Remedies Ltd a fundamentally strong company?
Indoco Remedies Ltd's fundamental strength based on key financial ratios
- Return on Capital (ROCE): 1.0%
Is Indoco Remedies Ltd debt free?
Indoco Remedies Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹1,000 Cr
What is Indoco Remedies Ltd's return on equity (ROE) and ROCE?
Indoco Remedies Ltd's return ratios over recent years
- FY2024: ROCE 10.0%
- FY2025: ROCE 0.0%
- FY2026: ROCE 1.0%
Is Indoco Remedies Ltd's cash flow positive?
Indoco Remedies Ltd's operating cash flow is positive (FY2026).
- Cash from Operations (CFO): ₹192 Cr
- Free Cash Flow (FCF): ₹90 Cr
What is Indoco Remedies Ltd's dividend yield?
Indoco Remedies Ltd's current dividend yield is 0.08%.
- Dividend Yield: 0.08%
- Current Price: ₹237
Who holds Indoco Remedies Ltd shares — promoters, FII, DII?
Indoco Remedies Ltd's shareholding pattern (Mar 2026)
- Promoters: 58.9%
- FII (Foreign): 0.9%
- DII (Domestic): 18.1%
- Public: 21.9%
Is promoter holding increasing or decreasing in Indoco Remedies Ltd?
Indoco Remedies Ltd's promoter holding has decreased recently.
- Current Promoter Holding: 58.9% (Mar 2026)
- Previous Quarter: 58.9% (Dec 2025)
- Change: -0.04% (decreasing — worth monitoring)
Is Indoco Remedies Ltd a new momentum entry or an established outperformer?
Indoco Remedies Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
Is Indoco Remedies Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Indoco Remedies Ltd may be worth studying
- Cash flow is positive — CFO ₹192 Cr
What is the investment thesis for Indoco Remedies Ltd?
Indoco Remedies Ltd investment thesis summary:
What is the future outlook for Indoco Remedies Ltd?
Indoco Remedies Ltd's forward outlook based on current data signals
- Insufficient data for a forward assessment — monitoring for more signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.